Scientists discovered that alcohol activates a sugar-producing pathway in the body, creating fructose that may reinforce addictive drinking. The enzyme responsible, KHK, appears to drive both alcohol cravings and liver injury. When this enzyme was blocked in mice, their drinking decreased and their livers showed far less damage.

Researchers developed a new nano-micelle formulation, CBD-IN, that finally gets CBD into the brain effectively. In mice, it relieved neuropathic pain quickly and didn’t cause the usual movement or memory side effects. Surprisingly, the pain relief didn’t use typical cannabinoid receptors, instead calming abnormal nerve activity more directly. The findings hint at new avenues for treating chronic pain and neurological diseases.

Scientists found that people who use both cannabis and tobacco show a distinct brain pattern tied to mood and stress regulation. Their scans revealed higher levels of an enzyme that reduces a natural feel-good molecule in the brain. This imbalance may help explain why co-users experience more anxiety and struggle more when quitting.

Almost 20% of packaged foods and beverages in the US contain synthetic dyes, often paired with excessive sugar to attract children. These additives have been linked to behavioral issues, yet remain widespread among major brands like Mars and PepsiCo. Experts criticize the FDA for relying on voluntary reform, contrasting it with Europe’s stricter labeling laws. Growing state-level action offers hope for meaningful change.

Using powerful 7-Tesla brain imaging, researchers mapped how the brainstem manages pain differently across the body. They discovered that distinct regions activate for facial versus limb pain, showing the brain’s built-in precision pain control system. The findings could lead to targeted, non-opioid treatments that use cannabinoid mechanisms instead of opioids, offering safer pain relief options.